<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ORAQIX- lidocaine and prilocaine gel </strong><br>DENTSPLY Pharmaceutical<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Oraqix safely and effectively. See full prescribing information for Oraqix.<br><br> ORAQIX<span class="Sup">®</span> (lidocaine and prilocaine periodontal gel) 2.5%/2.5%<br> Initial U.S. Approval:  2003</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Use the included blunt tipped applicator to apply gel to gingival margins and periodontal pockets. (<a href="#S2">2</a>)</li>
<li>May be reapplied as needed up to a maximum of 5 cartridges per treatment session. (<a href="#S2">2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Periodontal gel containing:  lidocaine 25 mg/mL and prilocaine 25 mg/mL. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to local anesthetics of the amide type (<a href="#S4">4</a>)</li>
<li>A history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of the product (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> (<a href="#S5.1">5.1</a>)</li>
<li>DO NOT INJECT (<a href="#S5.2">5.2</a>)</li>
<li>Allergic and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> can occur (<a href="#S5.3">5.3</a>)</li>
<li>Avoid contact with eyes (<a href="#S5.4">5.4</a>)</li>
<li>Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> (<a href="#S5.6">5.6</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence &gt; 15%) are <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">application site reactions</span> including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness, irritation, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, ulcerations, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> and/or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>. (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact DENTSPLY Pharmaceutical at 1-800-989-8826 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </span> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Other local anesthetics or agents structurally related to local anesthetics (<a href="#S7.1">7.1</a>)</li>
<li>Drugs associated with drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (<a href="#S7.2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy:  There have been no adequate and well-controlled studies in pregnant women. Oraqix should be used during pregnancy only if the benefits outweigh the risks. (<a href="#S8.1">8.1</a>)</li>
<li>Nursing Mothers:  Exercise caution when administering to a nursing woman. (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric Use:  Safety and effectiveness in pediatric patients have not been established. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Maximum Recommended Dosage</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	DO NOT INJECT</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Avoid Contact with Eyes</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	History of Drug Sensitivity</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Studies Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Other Local Anesthetics or Agents Structurally Related to Local Anesthetics</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Drugs inducing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1	Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5	Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1	Oraqix/Local anesthetic toxicity emergency</a></h2>
<h2><a href="#section-9.2" class="toc">10.2	Management of Oraqix/Local Anesthetic Emergencies</a></h2>
<h2><a href="#section-9.3" class="toc">10.3	<span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></a></h2>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2	Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3	Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<p class="First">Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	General Dosing Information</h2>
<p class="First"><span class="Bold">DO NOT INJECT <span class="Italics">[see<a href="#S5.2"> Warnings and Precautions (5.2)</a>]</span></span></p>
<p>Apply Oraqix on the gingival margin around the selected teeth using the blunt-tipped applicator included in the package. Wait 30 seconds, and then fill the periodontal pockets with Oraqix using the blunt-tipped applicator until the gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment. A longer waiting time does not enhance the anesthesia. Anesthetic effect, as assessed by probing of pocket depths, has a duration of approximately 20 minutes (individual overall range 14 – 31 minutes). If the anesthesia starts to wear off, Oraqix may be re-applied if needed.</p>
<p>Typically, 1 cartridge (1.7g) or less of Oraqix will be sufficient for one quadrant of the dentition.</p>
<p>When administered, Oraqix should be a liquid. If it has formed a gel, it should be placed in a refrigerator (do not freeze) until it becomes a liquid again. When in the liquid state, the air bubble visible in the cartridge will move if the cartridge is tilted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Maximum Recommended Dosage</h2>
<p class="First">The maximum recommended dose of Oraqix at one treatment session is 5 cartridges, i.e., 8.5g gel.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Periodontal gel containing:  lidocaine 25 mg/mL and prilocaine 25 mg/mL.</p>
<p>Each cartridge contains 1.7 mL (42.5 mg of lidocaine and 42.5 mg of prilocaine).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">Oraqix is contraindicated in patients with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to local anesthetics of the amide type or to any other component of the product.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></h2>
<p class="First">Prilocaine in Oraqix can cause elevated methemoglobin levels particularly in conjunction with methemoglobin-inducing agents. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has also been reported in a few cases in association with lidocaine treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> are more susceptible to drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. Oraqix should not be used in those patients with congenital or idiopathic <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> and in infants under the age of twelve months who are receiving treatment with methemoglobin-inducing agents. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> may be delayed some hours after exposure. Initial signs and symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> are characterized by a slate grey <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> seen in, e.g., buccal mucous membranes, lips and nail beds. In severe cases symptoms may include central <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, dysrhythmia and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> should be considered if central <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> unresponsive to oxygen therapy occurs, especially if metHb-inducing agents have been used. Calculated oxygen saturation and pulse oximetry are inaccurate in the setting of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. The diagnosis can be confirmed by an elevated methemoglobin level measured with co-oximetry. Normally, metHb levels are &lt;1%, and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> may not be evident until a level of at least 10% is present. The development of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is generally dose related. The individual maximum level of metHb in blood ranged from 0.8% to 1.7% following administration of the maximum dose of 8.5g Oraqix.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Underline">Management of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></span>: Clinically significant symptoms of <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> should be treated with a standard clinical regimen such as a slow intravenous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of methylene blue at a dosage of 1to 2 mg/kg given over a five minute period.</p>
<p>Patients taking drugs associated with drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> such as sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, and quinine are also at greater risk for developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. Treatment with Oraqix should be avoided in patients with any of the above conditions or with a previous history of problems in connection with prilocaine treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	DO NOT INJECT</h2>
<p class="First">Oraqix should not be used with standard dental syringes. Only use this product with the Oraqix blunt-tipped applicator, which is available from DENTSPLY Pharmaceutical.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></h2>
<p class="First">Allergic and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> associated with lidocaine or prilocaine in Oraqix can occur. These reactions may be characterized by <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. If these reactions occur they should be managed by conventional means.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Avoid Contact with Eyes</h2>
<p class="First">Oraqix coming in contact with the eye should be avoided because animal studies have demonstrated severe <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>. A loss of protective reflexes may allow corneal irritation and potential <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">abrasion</span>. If eye contact occurs, immediately rinse the eye with water or saline and protect it until normal sensation returns. In addition, the patient should be evaluated by an ophthalmologist, as indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	History of Drug Sensitivity</h2>
<p class="First">Patients allergic to paraminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine and/or prilocaine. However, Oraqix should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations of lidocaine and prilocaine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Studies Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice<span class="Italics">.</span></p>
<p>Although no major differences in adverse events between Oraqix and placebo-treated subjects were observed, all patients in the placebo-controlled studies received either Oraqix or a placebo gel (consisting of the vehicle in Oraqix without lidocaine or prilocaine). Therefore, it is not possible to determine if adverse events in each treatment group were attributable to the inactive ingredients comprising the Oraqix or vehicle or if adverse event rates were higher than expected background rates. Therefore, a causal relationship between the reported adverse reactions and Oraqix could neither be established nor ruled out.</p>
<p>Following SRP treatment with Oraqix in 391 patients, the most frequent adverse events were local reactions in the oral cavity (see following<a href="#table1"> table</a>). These events, which occurred in approximately 15% of patients, included <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness, irritation, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, ulcerations, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and/or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in the treated area. Of the 391 patients treated with Oraqix, five developed ulcerative lesions and two developed <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> of mild to moderate severity near the site of SRP. In addition, ulcerative lesions in or near the treated area were also reported for three out of 168 patients who received placebo. Other symptoms reported in more than one patient were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, flu, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span> and <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>/injury.</p>
<a name="table1"></a><table class="Noautorules" width="85%">
<caption><span>Table 1. Number (percent) of patients with adverse events occurring in more than one patient in any of the treatment groups. </span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead>
<tr><th align="left" colspan="4">Each patient is counted only once per adverse event. The occurrence in a single patient is included in this table if the same symptom has been seen in at least one patient in another group.</th></tr>
<tr class="Botrule Toprule">
<th class="Lrule Rrule" align="left">System Organ Class<br>Preferred Term</th>
<th class="Rrule" align="center">Oraqix gel<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(N = 391)<br>n (%)</th>
<th class="Rrule" align="center">Placebo gel<br>(N = 168)<br>n (%)</th>
<th class="Rrule" align="center">Lidocaine injection<a href="#footnote-1" class="Sup">*</a><br>(N = 170)<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>in a cross-over study, 170 subjects received either Oraqix or lidocaine injection 2% in each test period</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>includes complaints of bad or bitter taste lasting for up to 4 hours after administration of Oraqix</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>i.e. symptoms in the oral cavity</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>includes <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, soreness, irritation, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, ulcerations, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> and/or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> in the treated area</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Muscular-Skeletal System Disorders</span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center"><span class="Bold">1(0)</span></td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> and/or <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthropathy</span></td>
<td class="Rrule" align="center"><span class="Bold">1(0)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Central &amp; Peripheral Nervous System </span><br>Disorders</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center"><span class="Bold">8(2)</span></td>
<td class="Rrule" align="center"><span class="Bold">3(2)</span></td>
<td class="Rrule" align="center"><span class="Bold">5(3)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center"><span class="Bold">1(0)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Special Senses Other,  Disorders</span><br><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste Perversion</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center"><span class="Bold">8(2)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Gastro-Intestinal System Disorders</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center"><span class="Bold">3(1)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Infection</span></td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> 											</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">2 (1)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Body as a whole- General Disorders</span><br><span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">Accident</span> and/or Injury</td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center"><span class="Bold">3(1)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Flu-Like Disorder</td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (remote from application site)</td>
<td class="Rrule" align="center"><span class="Bold">1(0)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
<td class="Rrule" align="center"><span class="Bold">1(1)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">
<span class="Bold">Application Site Disorders<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span><br>Anesthesia Local</td>
<td class="Rrule" align="center"><span class="Bold">2(1)</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application Site Reaction</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center"><span class="Bold">52(13)</span></td>
<td class="Rrule" align="center"><span class="Bold">20(12)</span></td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Other Local Anesthetics or Agents Structurally Related to Local Anesthetics</h2>
<p class="First">Oraqix should be used with caution in combination with dental injection anesthesia, other local anesthetics, or agents structurally related to local anesthetics, e.g., Class 1 antiarrhythmics such as tocainide and mexiletine, as the toxic effects of these drugs are likely to be additive and potentially synergistic.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Drugs inducing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></h2>
<p class="First">Patients taking drugs associated with drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> such as sulfonamides, acetaminophen, acetanilide, aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin, primaquine, and quinine are also at greater risk for developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> <span class="Italics">[See<a href="#S10"> OVERDOSAGE (10)</a> and <a href="#s5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in rats with lidocaine, prilocaine and a 1:1 (weight:weight) mixture of the two compounds. There was no evidence of harm to the fetus at subcutaneous doses of up to 30 mg/kg lidocaine (estimated exposure was approximately equivalent to the expected lidocaine exposure at the maximum recommended human dose of Oraqix (lidocaine and prilocaine periodontal gel) 2.5% / 2.5% on a mg/m<span class="Sup">2</span> basis). Following intramuscular prilocaine doses of up to 300 mg/kg (estimated exposure was approximately 11 times the expected prilocaine exposure at the maximum recommended human dose of Oraqix gel on a mg/m<span class="Sup">2</span> basis), there was no evidence of impaired fertility or harm to the fetus. Similarly, subcutaneous administration of a lidocaine and prilocaine mixture of 40 mg/kg of each compound (estimated exposures were approximately 1.5 times the expected lidocaine and prilocaine exposures at the maximum recommended human dose of Oraqix gel on a mg/m<span class="Sup">2</span> basis) produced no teratogenic,  embryotoxic, or fetotoxic effects. Reproductive toxicology studies of lidocaine were also conducted in rabbits. There was no evidence of harm to the fetus at a dose of 5 mg/kg, s.c. (60 mg/m<span class="Sup">2</span>). Treatment of rabbits with 15 mg/kg (180 mg/m<span class="Sup">2</span>) produced evidence of maternal toxicity and evidence of delayed fetal development, including a non-significant decrease in fetal weight (7%) and an increase in minor skeletal anomalies (skull and sternebral defects, reduced ossification of the phalanges). The effects of lidocaine and prilocaine on post-natal development was examined in rats treated for 8 months with 10 or 30 mg/kg, s.c. lidocaine or prilocaine (60mg/m<span class="Sup">2</span> and 180 mg/m<span class="Sup">2</span> on a body surface area basis, respectively up to 1.4-fold the maximum recommended exposure for a single procedure). This time period encompassed 3 mating periods. There was no evidence of altered post-natal development in any offspring; however, both doses of either drug reduced the average number of pups per litter surviving until weaning of offspring from the first 2 mating periods. In a separate study, the effect of prilocaine on pre- and postnatal development was examined in rats treated with up to 60 mg/kg, s.c. (up to 2.8 times the maximum recommended human dose of prilocaine in Oraqix gel on a mg/m<span class="Sup">2</span> basis) from Day 6 of gestation to weaning. There was no evidence of altered post-natal development, viability, or reproductive capacity in any offspring.  All the above calculations of exposure are assuming 100% bioavailability of lidocaine and prilocaine after Oraqix administration. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Oraqix should be used during pregnancy only if the benefits outweigh the risks.</p>
<p>Reproduction studies on the Oraqix drug product, including the inactive ingredients, have not been conducted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First">Lidocaine and, possibly, prilocaine are excreted in breast milk. Caution should be exercised when Oraqix is administered   to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Very young children are more susceptible to <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. There have been reports of clinically significant <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> in infants and children following excessive applications of lidocaine 2.5% topical cream <span class="Italics">[See<a href="#S5.1"> Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Of the total number of subjects in clinical studies of Oraqix, 7% were aged 65 and over, while 1% were aged 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-9.1"></a><p></p>
<h2>10.1	Oraqix/Local anesthetic toxicity emergency</h2>
<p class="First">Oraqix used at the recommended doses is not likely to cause toxic plasma levels of lidocaine or prilocaine. However, if other local anesthetics are administered at the same time, e.g. topically or by injection, the toxic effects are thought to be additive and could result in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with systemic toxic reactions. There is generally an increase in severity of symptoms with increasing plasma concentrations of lidocaine and/or prilocaine. Systemic CNS toxicity may occur over a range of plasma concentrations of local anesthetics. CNS toxicity may typically be found around 5000 ng/mL of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL.</p>
<p>Pharmacological thresholds for prilocaine are poorly defined. Central nervous system (CNS) symptoms usually precede cardiovascular manifestations. The plasma level of lidocaine observed after the maximum recommended dose (5 cartridges) of Oraqix in 11 patients exposed over 3 hours ranged from 157to 552 ng/mL with a mean of 284 ng/mL ± 122 SD. The corresponding figure for prilocaine was 53-181 ng/mL with a mean of 106 ± 45 SD. <span class="Italics">[See <a href="#s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
<p>Systemic adverse effects of lidocaine and/or prilocaine are manifested by central nervous system and/or cardiovascular symptoms.</p>
<p>Clinical symptoms of systemic toxicity include CNS excitation and/or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (light-headedness, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, muscular <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and general <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>). Lidocaine and/or prilocaine may cause decreases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance and mean arterial pressure. These changes may be attributable to direct depressant effects of these local anesthetic agents on the cardiovascular system. Cardiovascular manifestations may include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-9.2"></a><p></p>
<h2>10.2	Management of Oraqix/Local Anesthetic Emergencies</h2>
<p class="First">Should severe CNS or cardiovascular symptoms occur, these may be treated symptomatically by, for example, the administration of anticonvulsive drugs, respiratory support and/or cardiovascular resuscitation as necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.3"></a><a name="section-9.3"></a><p></p>
<h2>10.3	<span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></h2>
<p class="First">For detailed information on <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> causes, symptoms, and treatment, see<a href="#S5.1"> Warnings and Precautions (5.1)</a>.</p>
<p>For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison control center <span class="Bold">(1-800-222-1222).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Oraqix (lidocaine and prilocaine periodontal gel,) 2.5%/2.5% is a microemulsion in which the oil phase is a eutectic mixture of lidocaine and prilocaine in a ratio of 1:1 by weight. This eutectic mixture has a melting point below room temperature; therefore, both local anesthetics exist as liquid oils rather than as crystals. Oraqix contains poloxamer excipients, which show reversible temperature-dependent gelation. Together with the lidocaine-prilocaine 1:1 mixture, the poloxamers form a low-viscosity fluid system at room temperature and an elastic gel in the periodontal pocket. Oraqix is administered into periodontal pockets, by means of the supplied special applicator. Gelation occurs at body temperature, followed by release of the local anesthetics, lidocaine and prilocaine. The Oraqix single-use glass cartridges deliver up to 1.7g (1.7mL) of gel (42.5 mg of lidocaine and 42.5 mg of prilocaine). Prilocaine base and lidocaine base are both relatively hydrophilic amino-amides.</p>
<p>The structural formulas are:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-01.jpg"></p>
<p>Lidocaine is chemically designated as 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide and has an octanol:water partition ratio of 43 at pH 7.4. The pKa of lidocaine is 7.86. Prilocaine is chemically designated as N-(2-methyl-phenyl)-2 (propylamino)-propanamide and has an octanol:water partition ratio of 25 at pH 7.4. The pKa of prilocaine is 7.89.</p>
<p>Each gram of Oraqix contains 25-mg lidocaine base and 25-mg prilocaine base. The gel also contains thermosetting agents (poloxamer 188 purified, poloxamer 407 purified), hydrochloric acid (pH adjustment), and purified water. The pH of Oraqix is 7.5-8.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Lidocaine and prilocaine belong to the amide class of local anesthetics. Both lidocaine and prilocaine block sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2	Pharmacodynamics</h2>
<p class="First">After application of Oraqix on the gingival margin and a waiting period of 30 seconds, additional Oraqix is applied directly into periodontal pockets to provide localized anesthesia. The onset of local anesthetic effect after application of Oraqix into the periodontal pocket occurs by 30 seconds and a longer waiting time does not enhance the anesthetic affect. Anesthetic effect, as assessed by probing of pocket depths, lasted for about 20 minutes (individual overall range 14 to 31 minutes).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Absorption:</span> Lidocaine and prilocaine are absorbed from Oraqix via the oral mucous membranes. After a single application of 0.9to 3.5 g Oraqix, the mean (±SD) lidocaine and prilocaine Cmax values were 182 (±53) and 77 (±27) ng/mL, respectively. After a total of 8 to 8.5 g Oraqix administered as repeated applications over 3 hours, the mean (±SD) lidocaine Cmax was 284 (±122) ng/mL, ranging between 157 and 552 ng/mL. The mean lidocaine AUC∞ was 84,000 ng.min/mL. The mean (±SD) prilocaine Cmax was 106 (±45) ng/mL, ranging between 53 and 181 ng/mL. The mean prilocaine AUC∞ was 26,000 ng.min/mL.</p>
<p>The increase in Cmax of both lidocaine and prilocaine is proportional (or less than proportional) to the dose after single application of Oraqix. The Cmax after a cumulative dose of 8.5 g Oraqix administered as repeated applications over 3 hours, (i.e. the highest recommended dose, corresponding to 212.5 mg each of lidocaine and prilocaine base), is lower than that extrapolated from the proportional increase in plasma concentrations at lower doses.</p>
<p>The median Tmax of lidocaine and prilocaine was 30 minutes, ranging between 20 and 40 min., after the start of a single application of 0.9 to 3.5 g Oraqix, and 200 minutes, ranging between 120 and 200 min., after a cumulative dose of 8.5g Oraqix administered as repeated applications over 3 hours.</p>
<p>The toxicities of lidocaine and prilocaine are thought to be additive. Systemic CNS toxicity may occur over a range of plasma concentrations of local anesthetics. CNS toxicity may typically be found around 5000 ng/mL of lidocaine, however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL. Pharmacological thresholds for prilocaine are poorly defined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Distribution:</span> Lidocaine and prilocaine have an intermediate degree of plasma protein binding, mainly to 1-acid glycoprotein, with a protein binding of 70% and 40%, respectively. When administered intravenously, the mean volume of distribution (for 60 kg person) at steady state for lidocaine and prilocaine were 90 L and 156 L, respectively. Oraqix is not intended for intravenous administration. Both lidocaine and prilocaine cross the placental and blood brain barriers, presumably by passive diffusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism: </span>Lidocaine and prilocaine are mainly metabolized in the liver. Prilocaine and lidocaine are not metabolized by plasma esterases.</p>
<p>The main metabolism of lidocaine is through N-dealkylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), which is mainly mediated by CYP3A4. These metabolites are hydrolyzed to 2,6-xylidine, which is converted to 4-hydroxy-2,6-xylidine (mediated by CYP2A6), the major urinary metabolite in man. After a total of 8 to 8.5g Oraqix administered as repeated applications over 3 hours, the mean (+SD) 2,6-xylidine Cmax was 18 (+8.4) ng/mL ranging between 8 and 32 ng/mL. The mean 2,6-xylidine AUC∞ was 9800 ng.min/mL (±6370), ranging between 3480 to 24,580 ng/min/mL). MEGX has an antiarrhythmic and convulsant activity similar to that of lidocaine and a somewhat longer half-life. GX has a weak antiarrhythmic effect but lacks convulsant activity and has a half-life of about 10 h.</p>
<p>Prilocaine is split at the amide linkage to o-toluidine, which is converted further to 4- and 6- hydroxytoluidine. The prilocaine metabolite o-toluidine and the hydroxylated metabolites of o-toluidine are excreted mainly in the urine. o-Toluidine has been shown to be carcinogenic in several animal models. After a total of 8 to 8.5g Oraqix was administered as repeated applications over 3 hours, the mean (±SD) o-toluidine Cmax was 25 (±11) ng/mL ranging between 13 and 44 ng/mL. The mean o-toluidine AUC∞ was 9200 ng.min/mL. The median Tmax was 220 minutes, ranging between 90 and 240 min. In addition, o-Toluidine can cause the formation of methemoglobin (metHb) following treatment with prilocaine. Individual maximum blood concentrations of metHb increased from 0 to 1.1% up to 0.8 to 1.7% following administration of the maximum recommended dose of 8.5g Oraqix administrated as repeated applications over 3 hours. The Tmax of metHb ranged from 1 to 4 hours. Normally, &lt;1 % of the total hemoglobin is in the form of metHb. <span class="Italics">[See<a href="#S10"> OVERDOSAGE (10)</a>]. </span>Patients with glucose-6-phosphate dehydrogenase deficiencies, and patients taking oxidizing drugs such as antimalarials and sulfonamides are more susceptible to drug-induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>. <span class="Italics">[See<a href="#S5.1"> Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Elimination:</span> Lidocaine and prilocaine have systemic clearances of 0.95 and 2.37 L/min, respectively, after intravenous administration as single agents. The terminal half-life of both drugs after intravenous administration as single agents is 1.6 h. Oraqix is not intended for intravenous administration.</p>
<p>However, after application of Oraqix to the periodontal pockets the mean (±SD) terminal lidocaine half-life was 3.6 (±1.3) hours, ranging between 2.2 and 6.5 h. The mean (±SD) terminal prilocaine half-life was 2.8 (±1.0) hours, ranging between 2.0 to 5.7 h. For the metabolite o-toluidine the mean terminal half-life was 4.0 (±1.1) hours, ranging between 2.0 and 5.7 hours. For the metabolite 2,6-xylidine the mean terminal half-life was 8.0 (±4.0) hours, ranging between 3.7 and 18.3 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Pediatrics:</span> The pharmacokinetics of lidocaine and prilocaine after Oraqix administration have not been studied in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Italics">Geriatrics:</span> The pharmacokinetics of lidocaine and prilocaine after Oraqix administration have not been studied in geriatric patients.  However, intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours). No studies in the intravenous pharmacokinetics of prilocaine in elderly patients have been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Italics">Special populations:</span> No pharmacokinetic studies were conducted to specifically address special populations. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: Lidocaine and prilocaine and their metabolites are known to be excreted by the kidney, and the metabolites may accumulate in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.9"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: The half-life of lidocaine may be prolonged two-fold or more in patients with liver dysfunction. Liver dysfunction may also alter prilocaine pharmacokinetics. Because of their inability to metabolize local anesthetics normally, patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, are at a greater risk of developing toxic plasma concentrations of lidocaine and prilocaine.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Italics">Carcinogenesis</span> - Long-term studies in animals have not been performed to evaluate the carcinogenic potential of either lidocaine or prilocaine. Chronic oral toxicity studies of o-toluidine, a metabolite of prilocaine, have shown that this compound is a carcinogen in both mice and rats. The tumors associated with o-toluidine included hepatocarcinomas/ <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female mice, multiple occurrences of <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span>/<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> in both sexes of mice, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> of multiple organs, transitional-cell carcinomas/<span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> of urinary bladder in both sexes of rats, subcutaneous <span class="product-label-link" type="condition" conceptid="4012174" conceptname="Fibroma">fibromas</span>/<span class="product-label-link" type="condition" conceptid="4202374" conceptname="Fibrosarcoma">fibrosarcomas</span> and <span class="product-label-link" type="condition" conceptid="4033891" conceptname="Mesothelioma">mesotheliomas</span> in male rats, and mammary gland fibroadenomas/<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in female rats. These findings were observed at the lowest tested dose of 150 mg/kg/day or greater over two years (estimated daily exposures in mice and rats were approximately 6 and 12 times, respectively, the estimated exposure to o-toluidine at the maximum recommended human dose of 8.5g of Oraqix gel on a mg/m<span class="Sup">2</span> basis). Thus, the no effect dose is less than 6 to 12 times the estimated exposure to o-toluidine at the maximum recommended human dose, assuming 100% bioavailability of prilocaine from the Oraqix gel. Complete conversion of prilocaine to its metabolite o-toluidine on a molar basis is assumed. This gives a conversion on a weight basis of about 50% for prilocaine base (dependent on the molecular weights, i.e. 220 for prilocaine base and 107 for o-toluidine).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Italics">Mutagenesis </span>- The mutagenic potentials of lidocaine and prilocaine have been tested in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reverse mutation assay, an in vitro chromosome aberrations assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and in an in vivo mouse micronucleus assay. There was no indication of any mutagenic effects for either compound in these studies.</p>
<p>o-Toluidine, metabolite of prilocaine, was positive in Escherichia coli DNA repair and phage-induction assays. Urine concentrates from rats treated orally with 300 mg/kg o-toluidine were mutagenic to <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium in the presence of metabolic activation. Several other tests on o-toluidine, including reverse mutations in five different <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with or without metabolic activation, and single strand breaks in DNA of V79 Chinese hamster cells, were negative.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Italics">Impairment of Fertility:</span> The effect of lidocaine on fertility was examined in the rat model. Administration of 30 mg/kg, s.c. (180 mg/m<span class="Sup">2</span> or 1.4 fold the maximum recommended human oral dose for one treatment session assuming 100% bioavailability of lidocaine) to the mating pair did not produce alterations in fertility or general reproductive performance of rats. There are no studies that examine the effect of lidocaine or prilocaine on sperm parameters. The effects of prilocaine on fertility was examined in rats treated for 8 months with 10 or 30 mg/kg, s.c. lidocaine or prilocaine (60 mg/m<span class="Sup">2</span> and 180 mg/m<span class="Sup">2</span> on a body surface area basis, respectively up to 1.4-fold the maximum recommended exposure for a single procedure assuming 100% bioavailability of lidocaine and prilocaine).  This time period encompassed 3 mating periods. There was no evidence of altered fertility.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<p class="First">A total of 337 patients (146 men and 191 women; 169 Oraqix and 168 placebo) were studied in three randomized, double-blind, placebo-controlled trials. Patients received a median dose of approximately 1 cartridge (1.7g gel), ranging from ¼ to 2½ cartridges per quadrant treated. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of Oraqix was assessed by asking patients to rate their <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on a continuous visual analog scale (VAS) from 0 (no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) to 100 mm (worst <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> imaginable). Patients were asked to report overall <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">procedural pain</span> 5 minutes following manual scaling and/or root planing (SRP) in a single quadrant that had been pre-treated with Oraqix or placebo (vehicle only, without lidocaine or prilocaine). In all three studies, patients were given Oraqix or placebo (vehicle only, without lidocaine or prilocaine). In all three studies, patients who were given Oraqix reported lower VAS scores during the procedure than those given placebo. Study B3 recruited patients with a known sensitivity to mechanical probing of dental pockets, whereas in studies B1 and B2, this was not a requirement. Results of B1, B2 and B3 are summarized below.</p>
<table width="75%">
<caption><span>Table 2. Visual Analog <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Scale (100 mm scale)</span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Study<br>(No. of patients)</th>
<th class="Rrule" align="left">Oraqix<br>Median VAS</th>
<th class="Rrule" align="left">Placebo<br>Median VAS</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">Visual Analog <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Scale</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>p&lt;0.05</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">B1 (n=122)<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="left">7</td>
<td class="Rrule" align="left">17</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">B2 (n=130)<a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="left">5</td>
<td class="Rrule" align="left">13</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">B3 (n=85)<a href="#footnote-5" class="Sup">*</a>
</td>
<td class="Rrule" align="left">11</td>
<td class="Rrule" align="left">27</td>
</tr>
</tbody>
</table>
<p>The trial also compared individual patient estimates of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on a 5-step categorical Verbal Rating Scale (VRS) which included the following categories: no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, moderate <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and very severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The results of those who reported no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> are shown in the test table.</p>
<table width="75%">
<caption><span>Table 3. Verbal Rating Scale </span></caption>
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Study<br>(No. of Patients)</th>
<th class="Rrule" align="left">Oraqix</th>
<th class="Rrule" align="left">Placebo</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">Number of Patients Reporting "no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>" or "mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>" during SRP</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>p&lt;0.05 in the statistical test of the full five categorical scale</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">B1 (n=122)<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="left">57 (90%)</td>
<td class="Rrule" align="left">38 (64%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">B2 (n=130)<a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="left">49 (78%)</td>
<td class="Rrule" align="left">51 (76%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">B3 (n=85)<a href="#footnote-6" class="Sup">*</a>
</td>
<td class="Rrule" align="left">30 (70%)</td>
<td class="Rrule" align="left">20 (48%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Oraqix (lidocaine and prilocaine periodontal gel), 2.5%/2.5%, is supplied in dental cartridges that provide 1.7g gel.</p>
<p>Individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-packaged cartridges of Oraqix are distributed in a carton of 20 (NDC 66312-110-20). Each individual <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package also contains a sterile blunt-tipped applicator. Each blunt-tipped applicator is for single use only.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature.]</p>
<p>At temperatures below +5°C Oraqix may become opaque. This opacity will disappear when the cartridge is warmed to room temperature.</p>
<p><span class="Bold">DO NOT FREEZE.</span> Some components of Oraqix may precipitate if cartridges are frozen. Cartridges should not be used if they contain a precipitate.</p>
<p>Do not use dental cartridge warmers with Oraqix. The heat will cause the product to gel.</p>
<p><span class="Bold">See FDA-approved patient labeling (<a href="#ppi">Patient Information</a>)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be cautioned to avoid injury to the treated area, or exposure to extreme hot or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> temperatures, until complete sensation has returned.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for DENTSPLY Pharmaceutical<br>York, PA 17404<br>By: Recipharm Karlskoga AB<br>Karlskoga, Sweden</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ppi"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">oraqix</span><span class="Sup">®</span><br>Guide to Working Needle-free</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-02.jpg"></div>
<p><span class="Bold">DISPENSER PREPARATION</span></p>
<table width="100%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<tbody class="Headless"><tr class="First Last">
<td align="left"><dl>
<dt class="Bold">1.</dt>
<dd>Press reset button.<br><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-03.jpg"></p>
</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">2.</dt>
<dd>Load Oraqix into Oraqix Dispenser and attach blunt-tipped applicator.<br>Please note: When administered, Oraqix should be a liquid. If it has formed a gel, place in a refrigerator [do not freeze] until it becomes a liquid again. When in the liquid state, the air bubble will move if the cartridge is tilted.<br><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-04.jpg"></p>
</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">3.</dt>
<dd>If desired, bend applicator tip with cap to improve access to the periodontal pocket. If a bend greater than 45 degrees is desired, a double bend technique is recommended.<br><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-05.jpg"></p>
</dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Bold">Note: To ensure optimal dispensing performance, the air bubble should be purged from the cartridge prior to use. To purge the air bubble, hold the dispenser vertically and press the paddle 1-2 times.</span></p>
<p><span class="Bold">CLINICAL APPLICATION</span></p>
<table width="100%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<tbody class="Headless">
<tr class="First">
<td align="left"><dl>
<dt class="Bold">1.</dt>
<dd>Apply Oraqix on the gingival margin around tooth by pressing the "paddle" on top of the dispenser.<br>Please note: There is a slight delay from when you hear the click to when Oraqix is dispensed.</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">2.</dt>
<dd>After 30 seconds place the tip of the blunt-tipped applicator to the base of the periodontal pocket. Express the Oraqix until the gel becomes visible at the gingival margin.<br>Please note: The total volume of Oraqix dispensed is dependent on the periodontal pocket space.</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">3.</dt>
<dd>Wait 30 seconds and begin treatment.<br>Please note: Waiting longer than 30 seconds does not enhance the anesthetic effect.</dd>
</dl></td>
</tr>
<tr class="Last">
<td align="left"><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-06.jpg"></p></td>
<td align="left"><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-07.jpg"></p></td>
<td align="left"><p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-08.jpg"></p></td>
</tr>
</tbody>
</table>
<p>NOTE: Some practice and experience with Oraqix may be required to achieve optimal results. For detailed information and to view a demonstration video, please visit www.oraqix.com and click on the Video Clip: Clinical Application of Oraqix in an Enhanced Therapeutic Approach to Nonsurgical Therapy by Casey Hein, RHD, MBA, in the Professional Portal. You may also call out Customer Service representatives at 800-225-2787 should you have any questions or concerns.</p>
<p><span class="Bold">CLEANING THE DISPENSER</span></p>
<table width="100%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<tbody class="Headless"><tr class="First Last">
<td align="left"><dl>
<dt class="Bold">1.</dt>
<dd>When treatment is complete, remove the empty cartridge and carefully remove the blunt-tipped applicator, keeping hands/fingers away from the contaminated tip.</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">2.</dt>
<dd>If necessary, wash the surface of the Dispenser to remove any debris, blood or saliva that may be present.</dd>
</dl></td>
<td align="left"><dl>
<dt class="Bold">3.</dt>
<dd>After cleaning, proceed to disinfection and/or sterilization, according to your office <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> control procedures and instructions on the Oraqix Dispenser directions for use. It is recommended the Dispenser be steam autoclaved after each use.</dd>
</dl></td>
</tr></tbody>
</table>
<p><span class="Underline">For better dentistry</span><br><span class="Bold">DENTSPLY</span>			PHARMACEUTICAL</p>
<p>www.oraqix.com</p>
<p>PHA01-0808-1.2<br>			Oraqix<span class="Sup">®</span> is a registered trademark of DENTSPLY International, Inc. and/or its subsidiaries.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Gel Cartidge Carton</span></p>
<p>NDC 66312-110-20<br><span class="Bold">Rx only</span></p>
<p><span class="Bold Italics">oraqix</span><span class="Sup">®</span></p>
<p><span class="Bold"><span class="Italics">(lidocaine and prilocaine periodontal gel) 2.5% / 2.5%</span><br>Local Anesthetic for Periodontal Use</span></p>
<p>To be applied in periodontal pockets by the sterile blunt-tipped applicator included with<br>the pack. Please see enclosed package insert for full prescribing information.</p>
<p><span class="Bold">20 cartridges x 1.7</span> g gel<br><span class="Bold">Not for injection.</span></p>
<p><span class="Bold">DENTSPLY</span><br>PHARMACEUTICAL</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Gel Cartidge Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Dispenser Carton</span></p>
<p><span class="Bold Italics">oraqix</span><span class="Sup">®</span></p>
<p><span class="Bold">Dispenser</span></p>
<p><span class="Bold">Not for Injection</span></p>
<p>PN 66400 						</p>
<p><span class="Bold">DENTSPLY</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Dispenser Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b501d239-923b-48b2-82ed-6c5c253a67e2&amp;name=oraqix-10.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ORAQIX 		
					</strong><br><span class="contentTableReg">lidocaine and prilocaine gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66312-110</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">PERIODONTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lidocaine</strong> (lidocaine) </td>
<td class="formItem">lidocaine</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>prilocaine</strong> (prilocaine) </td>
<td class="formItem">prilocaine</td>
<td class="formItem">25 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>poloxamer 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>poloxamer 407</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66312-110-20</td>
<td class="formItem">20  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.7 g in 1 CARTRIDGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021451</td>
<td class="formItem">01/02/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>DENTSPLY Pharmaceutical
							(102221942)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Recipharm Karlskoga</td>
<td class="formItem"></td>
<td class="formItem">351250415</td>
<td class="formItem">MANUFACTURE(66312-110)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a5e6a6c7-c452-45fa-94f2-aae8391de28b</div>
<div>Set id: b501d239-923b-48b2-82ed-6c5c253a67e2</div>
<div>Version: 6</div>
<div>Effective Time: 20120820</div>
</div>
</div> <div class="DistributorName">DENTSPLY Pharmaceutical</div></p>
</body></html>
